Fig. 1Flow chart showing the process for selection of members
of the study cohort.
Fig. 2Adjusted incidence rate ratios (IRRs) of infection-related hospitalizations in diabetes and matched non-diabetes controls, stratified by age, sex, comorbidities, and the use of insulin. The IRRs were estimated using Poisson models. CI, confidence interval.
Table 1Baseline characteristics among diabetics and non-diabetic controls
Characteristic |
DM (n=66,426) |
Non-DM (n=132,852) |
P value |
Age, yr |
58.2±13.3 |
58.2±13.3 |
0.740 |
Female sex |
33,484 (50.4) |
66,968 (50.4) |
1.000 |
Household incomea
|
|
|
<0.001 |
Upper 30% |
15,524 (30.1) |
28,730 (26.2) |
Mid 40% |
22,746 (44.2) |
48,942 (44.6) |
Lower 30% |
13,216 (25.7) |
32,037 (29.2) |
Time since diagnosis, yr |
|
|
|
0–3 |
42,085 (63.4) |
≥4 |
24,341 (36.6) |
Drugs |
|
|
|
Use of glucose-lowering drugs |
|
|
|
Metformin |
26,490 (39.9) |
Sulfonylureas |
40,535 (61.0) |
Thiazolidinediones |
7,215 (10.9) |
Insulin |
12,648 (19.0) |
Other GLDs |
16,949 (25.5) |
Anthihypertensive drugs |
45,243 (68.1) |
54,200 (40.8) |
<0.001 |
ACEi/ARB |
19,358 (29.1) |
15,746 (11.8) |
<0.001 |
Dihydropyridines |
31,307 (47.1) |
36,412 (27.4) |
<0.001 |
Diuretics |
25,796 (38.8) |
32,708 (24.6) |
<0.001 |
β-Blockers |
23,178 (34.9) |
28,886 (21.7) |
<0.001 |
Statin |
21,103 (31.8) |
13,234 (10.0) |
<0.001 |
Aspirin |
26,715 (40.2) |
27,396 (20.6) |
<0.001 |
Comorbidity |
|
|
|
Hypertension |
47,933 (72.2) |
56,564 (42.6) |
<0.001 |
Dyslipidemia |
41,487 (62.5) |
30,291 (22.8) |
<0.001 |
Cardiovascular disease |
5,469 (8.2) |
4,276 (3.2) |
<0.001 |
Myocardial infarction |
1,479 (2.2) |
990 (0.7) |
<0.001 |
Heart failure |
1,135 (1.7) |
667 (0.5) |
<0.001 |
Stroke |
3,338 (5.0) |
3,202 (2.4) |
<0.001 |
PAD |
628 (0.9) |
213 (0.2) |
<0.001 |
Chronic kidney disease |
828 (1.2) |
213 (0.2) |
<0.001 |
Table 2Incidence rates of infection-related hospitalizations among diabetics and non-diabetic controls
Type of infection |
People with diabetes |
Control |
Diabetes vs. Control |
No. of events |
Event rate (per 1,000 yr) |
No. of events |
Event rate (per 1,000 yr) |
IRR (95% CI) |
Adjusted IRR (95% CI) |
Gastrointestinal |
8,005 |
14.66 |
5,448 |
5.42 |
2.71 (2.61–2.80) |
2.04 (1.95–2.13) |
Mycoses |
|
|
|
|
|
|
Candidiasis |
2,709 |
4.96 |
2,960 |
2.94 |
1.68 (1.60–1.77) |
1.36 (1.28–1.46) |
Other fungal |
1,392 |
2.55 |
1,220 |
1.21 |
2.10 (1.94–2.27) |
1.17 (1.06–1.29) |
Infective otitis externa |
289 |
0.53 |
803 |
0.80 |
0.66 (0.58–0.76) |
0.76 (0.64–0.90) |
Otitis media & mastoiditis |
772 |
1.41 |
637 |
0.63 |
2.23 (2.01–2.48) |
2.29 (1.98–2.63) |
Respiratory |
19,578 |
35.84 |
19,478 |
19.37 |
1.85 (1.81–1.89) |
1.76 (1.72–1.81) |
Pneumonia |
13,743 |
25.16 |
12,195 |
12.13 |
2.07 (2.02–2.13) |
1.57 (1.52–1.62) |
Hepatic abscess |
310 |
0.57 |
325 |
0.32 |
1.76 (1.50–2.05) |
10.17 (7.04–14.67) |
Cholecystitis |
2,695 |
4.93 |
3,314 |
3.30 |
1.50 (1.42–1.57) |
1.33 (1.25–1.41) |
Skin |
|
|
|
|
|
|
Cellulitis |
2,536 |
4.64 |
2,878 |
2.86 |
1.62 (1.54–1.71) |
1.52 (1.42–1.63) |
Other |
2,123 |
3.89 |
1,548 |
1.54 |
2.52 (2.36–2.70) |
3.52 (3.20–3.88) |
Bone and joint infections |
1,114 |
2.04 |
1,414 |
1.41 |
1.45 (1.34–1.57) |
1.74 (1.57–1.94) |
Myositis, synovitis and tenosynovitis |
372 |
0.68 |
354 |
0.35 |
1.93 (1.67–2.24) |
2.84 (2.24–3.61) |
Urinary tract infection |
13,172 |
24.12 |
10,837 |
10.78 |
2.24 (2.18–2.30) |
1.83 (1.77–1.89) |
Upper |
3,013 |
5.52 |
2,315 |
2.30 |
2.40 (2.27–2.53) |
1.78 (1.66–1.91) |
Lower |
10,159 |
18.60 |
8,522 |
8.47 |
2.19 (2.13–2.26) |
1.85 (1.78–1.92) |
CNS infection |
388 |
0.71 |
112 |
0.11 |
6.38 (5.17–7.87) |
8.72 (6.64–11.45) |
Sepsis |
3,438 |
6.29 |
3,062 |
3.04 |
2.07 (1.97–2.17) |
2.21 (2.07–2.36) |
Table 3Incidence rates of intensive care unit admissions and deaths among diabetics and non-diabetic controls
Type of infection |
People with diabetes |
Control |
Diabetes vs. Control |
No. of events |
Event rate (per 1,000 yr) |
No. of events |
Event rate (per 1,000 yr) |
IRR (95% CI) |
Adjusted IRR (95% CI) |
Gastrointestinal |
876 |
1.60 |
777 |
0.77 |
2.08 (1.88–2.29) |
2.06 (1.81–2.35) |
Mycoses |
|
|
|
|
|
|
Candidiasis |
254 |
0.47 |
583 |
0.58 |
0.80 (0.69–0.93) |
0.63 (0.53–0.74) |
Other fungal |
342 |
0.63 |
490 |
0.49 |
1.28 (1.12–1.47) |
0.43 (0.37–0.50) |
Infective otitis externa |
23 |
0.04 |
0 |
0.00 |
|
|
Otitis media & mastoiditis |
48 |
0.09 |
42 |
0.04 |
2.10 (1.39–3.18) |
1.65 (0.96–2.84) |
Respiratory |
1,483 |
2.72 |
863 |
0.86 |
3.16 (2.91–3.44) |
2.94 (2.64–3.29) |
Pneumonia |
3,603 |
6.60 |
3,991 |
3.97 |
1.66 (1.59–1.74) |
0.98 (0.93–1.04) |
Hepatic abscess |
50 |
0.09 |
0 |
0.00 |
|
|
Cholecystitis |
386 |
0.71 |
509 |
0.51 |
1.40 (1.22–1.59) |
1.09 (0.93–1.27) |
Skin |
|
|
|
|
|
|
Cellulitis |
136 |
0.25 |
495 |
0.49 |
0.51 (0.42–0.61) |
0.46 (0.36–0.59) |
Other |
214 |
0.39 |
56 |
0.06 |
7.04 (5.24–9.44) |
11.75 (7.32–18.86) |
Bone and joint infections |
119 |
0.22 |
35 |
0.03 |
6.26 (4.29–9.13) |
4.78 (3.09–7.39) |
Myositis, synovitis and tenosynovitis |
37 |
0.07 |
29 |
0.03 |
2.35 (1.44–3.82) |
1.43 (0.81–2.54) |
Urinary tract infection |
1,850 |
3.39 |
2,126 |
2.11 |
1.60 (1.50–1.70) |
1.01 (0.94–1.09) |
Upper |
292 |
0.53 |
100 |
0.10 |
5.38 (4.28–6.75) |
2.74 (2.11–3.56) |
Lower |
1,558 |
2.85 |
2,026 |
2.01 |
1.42 (1.32–1.51) |
0.91 (0.84–0.99) |
CNS infection |
137 |
0.25 |
35 |
0.03 |
7.21 (4.97–10.45) |
5.25 (3.53–7.79) |
Sepsis |
1,359 |
2.49 |
777 |
0.77 |
3.22 (2.95–3.52) |
3.49 (3.05–3.92) |